MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
在IFCT-0701 MAPS 3期试验中,miR-193b-3p和miR-132-3p作为接受一线贝伐单抗联合培美曲塞-铂类化疗的胸膜间皮瘤患者生存预后生物标志物。
期刊:Translational Oncology
影响因子:4.1
doi:10.1016/j.tranon.2025.102520
Levallet, Guénaëlle; Creveuil, Christian; Léger-Vigot, Alexandre; Brosseau, Solenn; Danel, Claire; Scherpereel, Arnaud; Lantuejoul, Sylvie; Mazières, Julien; Greillier, Laurent; Audigier-Valette, Clarisse; Bergot, Emmanuel; Moro-Sibilot, Denis; Molinier, Olivier; Léna, Hervé; Monnet, Isabelle; Morin, Franck; Gounant, Valérie; Zalcman, Gérard